The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Novo Nordisk's shares rebounded 4.7% in early trading on Friday after the FDA vowed to crack down on companies mass-marketing illegal copies of Wegovy. This followed a sharp sell-off triggered by Hims & Hers' launch of a cheap $49 compounded version. Understand the safety risks and what this means for GLP-1 patients seeking approved weight-loss treatments.
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
Super Bowl LX ads are packed with celebrities from Kendall Jenner to George Clooney, cutting-edge AI demos, and a surge in health spots promoting GLP-1 weight-loss drugs like Ozempic and Wegovy. As viewership hits record highs, advertisers are betting big on telehealth and pharma amid booming demand. This preview reveals the trends shaping America's biggest ad showdown.
Shares in Novo Nordisk, maker of Ozempic and Wegovy, plunged 18% after a sales warning flagged up to 13% decline in the US market due to falling GLP-1 drug prices. Despite 2025 sales growth of 6% to 309 billion kronor, the stock wipeout erased $32 billion in value. CEO Mike Doustdar highlights the upcoming Wegovy pill as a key future driver.
When 7-year-old Jessa injected her mom's Ozempic thinking it was stomach medicine, she faced severe vomiting, dehydration, and kidney risks. This incident underscores the dangers of GLP-1 medications like semaglutide and tirzepatide in children. Discover prevention tips and what to do in an emergency.
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but older adults face heightened risks like muscle loss and fractures. This guide breaks down the science-backed concerns, monitoring strategies, and when to avoid them. Stay informed to make safer health choices.
When Bollywood star Tamanna Bhatia appeared slimmer, social media buzzed with Ozempic accusations, sparking debates on beauty standards and rapid weight loss. Beyond the rumors, Ozempic (semaglutide) is a powerful GLP-1 drug transforming weight management. This guide dives into the science, risks, and healthier paths forward.
BPC-157 promises rapid healing for injuries and inflammation, but nearly all evidence comes from animal studies with scant human trials. As hype surges in wellness circles and amid policy shifts, experts urge caution due to safety unknowns and FDA prohibitions. This guide breaks down the science, risks, and what patients need to know.
GLP-1 drugs are revolutionizing weight loss, but workplace access risks creating inequities. This guide explores the clinical science behind Ozempic, Wegovy, Mounjaro, and Zepbound, plus employer strategies for inclusive well-being. Pair meds with nutrition and support for lasting results.
